Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

Zelicapavir Demonstrates High Clinical and Functional Barrier Against Antiviral Resistance: Results from a Randomized Double-Blind Placebo-Controlled Pediatric RSV Antiviral Clinical Trial

Saturday, April 18, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the positive results from a randomized double-blind placebo-controlled trial of Zelicapavir, which demonstrated a high clinical and functional barrier against antiviral resistance in treating pediatric Respiratory Syncytial Virus (RSV). The findings suggest that Zelicapavir could be a promising antiviral option for children affected by RSV.
Price reaction · baseline $14.01 (2026-04-17 close) · clean, no other ENTA news in the window
day 0 close · peak
-1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Zelicapavir shows a high clinical barrier against antiviral resistance.
  • The trial was randomized and double-blind, ensuring reliable results.
  • Results indicate potential effectiveness in treating pediatric RSV.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is Zelicapavir?

Zelicapavir is an antiviral drug being tested for its effectiveness against Respiratory Syncytial Virus (RSV).

What were the results of the pediatric RSV trial?

The trial showed that Zelicapavir has a high clinical and functional barrier against antiviral resistance.

Was the trial randomized?

Yes, the trial was randomized and double-blind, ensuring the reliability of the results.

Who conducted the trial?

The trial was conducted to evaluate the efficacy of Zelicapavir in treating pediatric RSV.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare Zelicapavir RSV pediatric trial antiviral resistance
Last updated: Apr 18, 2026

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →